Late Breaking Abstract - Thromboembolic complications in COVID-19 patients admitted to two large East London hospitals

Image-based recommendations for the evaluation of pulmonary embolism and arterial hypertension: what? when? how?

In-depth risk stratification in pulmonary arterial hypertension

EmPHasis-10 health-related quality of life score predicts outcomes in patients with idiopathic and connective tissue disease-associated pulmonary arterial hypertension: results from a UK multi-centre study

Standardised exercise training is feasible, safe and effective in pulmonary arterial and chronic thromboembolic pulmonary hypertension - results from a large European multicentre randomised controlled trial

REPAIR: long-term effects of macitentan on the right ventricle (RV) in pulmonary arterial hypertension (PAH)

Long-term outcomes in incident pulmonary arterial hypertension (PAH) patients initiated with triple combination therapy including parenteral prostacyclin (PGI2)

Long-term outcomes with initial triple oral therapy in pulmonary arterial hypertension (PAH): Insights from TRITON

Combination therapy with sotatercept analog RAP-011 is superior to sildenafil alone in severe experimental PAH and RAP-011 benefits persist after treatment cessation

ERS statement on chronic thromboembolic pulmonary hypertension